<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005958</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067939</org_study_id>
    <secondary_id>AMGEN-GCSF-990125</secondary_id>
    <secondary_id>NCI-V00-1594</secondary_id>
    <nct_id>NCT00005958</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer</brief_title>
  <official_title>Treatment of Patients With Transitional-Cell Carcinoma of the Urothelial Tract With Gemcitabine, Docetaxel and Filgrastim</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Colony-stimulating factors such as filgrastim may increase the&#xD;
      number of immune cells found in bone marrow or peripheral blood and may help a person's&#xD;
      immune system recover from the side effects of chemotherapy.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with&#xD;
      gemcitabine and docetaxel plus filgrastim in treating patients who have locally recurrent or&#xD;
      advanced urothelium cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the efficacy of gemcitabine, docetaxel, and filgrastim (G-CSF) in&#xD;
      patients with locally recurrent or advanced transitional cell carcinoma of the urothelial&#xD;
      tract. II. Determine the toxicity of this regimen in these patients. III. Determine the&#xD;
      disease-free and overall survival of this patient population treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to prior chemotherapy&#xD;
      (yes vs no). Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and docetaxel IV&#xD;
      over 1 hour on day 8. Patients also receive filgrastim (G-CSF) subcutaneously daily beginning&#xD;
      on day 9 and continuing until blood counts recover. Treatment continues every 3 weeks for 4&#xD;
      courses in the absence of disease progression or unacceptable toxicity. Patients who respond&#xD;
      to treatment may undergo surgery and 6-8 weeks later receive 2 more courses of chemotherapy.&#xD;
      Patients are followed every 3 months for 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 23-40 patients who have not received prior chemotherapy and 23&#xD;
      patients who have received prior chemotherapy will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 1999</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Bladder Cancer</condition>
  <condition>Transitional Cell Cancer of the Renal Pelvis and Ureter</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven locally recurrent or advanced transitional&#xD;
        cell carcinoma (TCC) of the urothelial tract (bladder, renal pelvis, or ureter) or TCC with&#xD;
        squamous cell or glandular elements not amenable to curative treatment No pure squamous&#xD;
        cell carcinoma or adenocarcinoma Regional or distant metastases after cystoprostatectomy No&#xD;
        brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: Karnofsky 80-100% Life&#xD;
        expectancy: At least 3 months Hematopoietic: No hemorrhagic disorder Absolute neutrophil&#xD;
        count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 10.0 g/dL&#xD;
        Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) SGOT no greater&#xD;
        than 3 times ULN Renal: Creatinine no greater than 2.0 mg/dL Other: Not pregnant or nursing&#xD;
        Negative pregnancy test Fertile patients must use effective contraception No known&#xD;
        sensitivity to any products to be administered or E. coli derived products No prior other&#xD;
        malignancy except inactive nonmelanoma skin cancer, adequately treated stage I or II cancer&#xD;
        in complete remission, or early stage prostate cancer (not currently being treated) No&#xD;
        illness or psychiatric condition that would preclude study or follow up Not previously&#xD;
        entered in this study No active uncontrolled infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: No other concurrent biologic therapy No&#xD;
        concurrent WBC transfusions Chemotherapy: No prior gemcitabine or docetaxel Other prior&#xD;
        chemotherapy allowed Prior intravesical therapy allowed No other concurrent chemotherapy&#xD;
        Endocrine therapy: Not specified Radiotherapy: Prior radiotherapy to renal pelvis or ureter&#xD;
        allowed Surgery: See Disease Characteristics Cystoprostatectomy or nephroureterectomy for&#xD;
        localized TCC allowed Other: No prior investigational drugs No other concurrent&#xD;
        investigational therapy No concurrent acetaminophen for fever prophylaxis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Tam</last_name>
    <role>Study Chair</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sacramento Center for Hematology and Medical Oncology</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Cancer Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Hematology-Oncology</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology-Hematology Associates of North Illinois, Ltd.</name>
      <address>
        <city>Gurnee</city>
        <state>Illinois</state>
        <zip>60031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Center for Cancer Medicine and Blood Disorders</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Medical Center</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology &amp; Oncology Associates of Southern Michigan</name>
      <address>
        <city>Jackson</city>
        <state>Michigan</state>
        <zip>49201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates of Central New York</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13217-6962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memphis Cancer Center, Inc.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arlington Cancer Center</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Virginia Oncology Group</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2001</verification_date>
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>April 19, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2004</study_first_posted>
  <last_update_submitted>December 3, 2013</last_update_submitted>
  <last_update_submitted_qc>December 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2013</last_update_posted>
  <keyword>stage III bladder cancer</keyword>
  <keyword>recurrent bladder cancer</keyword>
  <keyword>stage IV bladder cancer</keyword>
  <keyword>transitional cell carcinoma of the bladder</keyword>
  <keyword>metastatic transitional cell cancer of the renal pelvis and ureter</keyword>
  <keyword>regional transitional cell cancer of the renal pelvis and ureter</keyword>
  <keyword>recurrent transitional cell cancer of the renal pelvis and ureter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Ureteral Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

